This page provides a list of some of the company’s key events in the near future. An Investor Relations calendar can be found here.
- Press Releases
- Earnings Releases
- First North
- Insider trading
Public materials related to our company and products will be presented on this page. Presentations in Finnish language can be found here. Please note that these presentations are provided for historical use only. Herantis will not keep these presentations up-to-date after their actual presenting date.
Links to public video presentations are provided on this page. Video presentation in Finnish language can be found here.
Videos specific to the drug candidates of Herantis can be found under Patients
PLEASE NOTE: the presentations are for historical use only. The presentations are not kept up-to-date after their actual presenting date.
"In digital health, we only invest in Nordics and the USA." (An international life sciences investor)
Did you know that Bioethics is a very broad and challenging branch of science with potentially significant impact on our future?
The big difference in biotech investments compared to more established businesses is that you need to assess a possible future success rather than consider existing cash flow and profit.
Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?
Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?
The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.
The development of new drugs is always risky. The more innovative an approach is the higher are the risks. For a real breakthrough in an unmet clinical need, high risk acceptance is needed.
Seppo Nieminen, a Parkinson's patient active in the regional Parkinson's group of Keski-Uusimaa in Finland, gives his thoughts on the current publishing practice on news in Parkinson's.